| Value | ₹935.0 Cr |
|---|
NSE filing, NSE: GABRIEL. Summary written from the filing by ALFA Finder's alert engine.
Gabriel India Ltd: key numbers
- Share price
- ₹1,425.00
- Market cap
- ₹25,255 Cr
- Revenue (annual)
- ₹4,667 Cr
- Net profit (annual)
- ₹252.3 Cr
- P/E (TTM)
- 71.8×Sector 30.5×
- Promoter holding
- 66.29%+2.74% QoQ
- FII holding
- 5.91%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gabriel India Ltd
All →Gabriel India Earnings Call Transcript: Key Takeaways
Gabriel India reports strong consolidated revenue growth driven by aggressive portfolio diversification through new joint ventures with Faurecia and Mando.
Gabriel India Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue Rs16,080Mn (+22.9% YoY); EBITDA Rs1,409Mn at 8.8% margin, down ~80bps YoY. Forvia PV seat JV announced.
Gabriel India Dividend
Gabriel India declared an interim dividend of Rs 2.15 per share on 30 October 2026. Record date is 6 November 2026; payment due by 28 November.
Gabriel India Q2 FY27 Results: Net Profit ₹124 Cr, Up 15.8% YoY
Gabriel India Ltd reported revenue from operations of ₹1,608 Cr (+22.9% YoY) and net profit of ₹124 Cr (+15.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹124 Cr · +15.8% YoY
Gabriel India Board Meeting Date
Gabriel India will hold a board meeting on October 30, 2026 to consider unaudited results and an interim dividend. The record date for the proposed dividend is November 6, 2026.
Gabriel India Other Announcement
The company submitted its quarterly shareholding pattern report for the period ending September 30, 2026, as required under SEBI regulations.
Other acquisition announcements
All →Kalpataru Acquisition Worth ₹52.55 Cr
Kalpataru's subsidiary KPL approved acquiring 16.67% of step-down subsidiaries AREPL and AREDPL for ₹52.55 Crore. This makes them wholly owned, giving Kalpataru 100% of Kalpataru Parkcity project cash flows at Thane.
- Value
- ₹52.55 Cr
- Execution
- 60 days, subject to receipt of requisite approvals
Zydus Lifesciences Acquisition Worth ₹84 Cr
Zydus Lifesciences acquired Sterling Biotech's API business for Rs. 84 Crore via slump sale. The deal covers fermentation-based API products and is completed.
- Value
- ₹84.00 Cr
Zydus Lifesciences Acquisition Worth ₹167 Cr
Zydus Lifesciences completed acquisition of Sterling Biotech's API business for Rs. 167 Crore. The slump sale of fermentation-based API products strengthens its manufacturing portfolio.
- Value
- ₹167.0 Cr
Zydus Lifesciences Acquisition
Zydus Lifesciences completed its acquisition of Sterling Biotech's API business under a September 2024 Business Transfer Agreement. No transaction value was disclosed in this filing.
Arvaya Healthcare Acquisition
Arvaya Healthcare completed the acquisition of 100% equity in Sushodha Institute of Gastroenterology Private Limited on 1 November 2026. The target is now a wholly-owned subsidiary, with no consideration amount disclosed.
Affle 3I Acquisition Worth ₹3,990 Cr
Affle 3i's step-down subsidiary will acquire Perion Network in an all-cash deal valued at about ₹3,990 Crore. Closing is expected in early 2027.
- Value
- ₹3,990 Cr
- Execution
- Expected to close in early 2027